New Orphazyme CEO has great ambitions: Wants to create new Genmab
Christophe Bourdon, who has just taken on the role of CEO at Orphazyme, wants to work on reestablishing the confidence in the company, which suffered greatly following the firm's recent clinical failure.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Orphazyme's newly appointed CEO Christophe Bourdon certainly does not lack ambition. Within the next ten years, he sees potential for turning Orphazyme into the new Genmab – but with a focus on rare diseases, according to Danish newspaper Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme share recovers somewhat after dive
For subscribers
